Novartis (NVS)
(Delayed Data from NYSE)
$113.77 USD
-0.09 (-0.08%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $113.76 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.77 USD
-0.09 (-0.08%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $113.76 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum B VGM
Zacks News
Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?
by Zacks Equity Research
Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales of Glaxo's (GSK) Vaccines segment is likely to drive the top line in the first quarter.
Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.
Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
by Zacks Equity Research
Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.
Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales
by Zacks Equity Research
Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.
Marijuana ETF Down 9% in Past Month: Time to Enter the Space?
by Sanghamitra Saha
Growing global acceptance, increasing legalization and beaten-down prices open up room for marijuana ETF investing.
Allergan Falls as Supreme Court Dismisses Restasis Litigation
by Zacks Equity Research
Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
by Zacks Equity Research
Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
by Kinjel Shah
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Ophthotech Gets Rights to Gene Therapy for BEST Disease
by Zacks Equity Research
Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.
Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon
by Zacks Equity Research
Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Intercept Reports Additional Positive Data From NASH Study
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.
Top Research Reports for McDonald's, Enterprise Products & Charles Schwab
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), Enterprise Products Partners (EPD) and Charles Schwab (SCHW).
Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval
by Zacks Equity Research
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity.
Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
by Kinjel Shah
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig
by Zacks Equity Research
Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.
The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, 3M, Novartis, Schlumberger and ICICI
Achillion Meets Enrollment Target in Kidney Disease Studies
by Zacks Equity Research
Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.